Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2019 17:12 ET | Source: Paratek Pharmaceuticals

Paratek Awarded BARDA Project BioShield Contract for NUZYRA®

- Total award valued at up to $285 million - Paratek to host a conference call today, December 18, 2019 at 5:30 p.m. EST BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc....
December 02, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
November 12, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019

-- Third Quarter 2019 NUZYRA® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million -- -- Oral-only CABP Pharmacokinetics Study Initiated-- BOSTON, Nov. 12, 2019 (GLOBE...
November 04, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019

BOSTON, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
November 01, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
October 31, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections

BOSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
October 17, 2019 16:05 ET | Source: Paratek Pharmaceuticals

Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia

Application approvable by European Medicine Agency (EMA) for skin infections based on two Phase 3 studiesEMA requesting second study in CABP to meet regulatory standards of two Phase 3 studiesCompany...
October 01, 2019 16:30 ET | Source: Paratek Pharmaceuticals

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
September 25, 2019 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019

BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
September 09, 2019 08:00 ET | Source: Paratek Pharmaceuticals

Paratek Mourns Passing of Co-founder Dr. Stuart Levy

BOSTON, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) mourns the loss of Stuart Levy, M.D., who passed way last week. Dr. Levy co-founded the company more than two...